Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41)

An open-label, randomised phase 3 trial

André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Louis Baez-Diaz, Shakir Sarwar, Richard G. Margolese, William B. Farrar, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

Background: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients. Methods: For this open-label, randomised phase 3 trial we recruited women aged 18 years or older with an ECOG performance status of 0 or 1 with operable HER2-positive breast cancer. Each received four cycles of standard doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 intravenously on day 1 every 3 weeks followed by four cycles of weekly paclitaxel (80 mg/m2) intravenously on days 1, 8, and 15, every 4 weeks. Concurrently with weekly paclitaxel, patients received either trastuzumab (4 mg/kg load, then 2 mg/kg intravenously) weekly until surgery, lapatinib (1250 mg orally) daily until surgery, or weekly trastuzumab plus lapatinib (750 mg orally) daily until surgery. After surgery, all patients received trastuzumab to complete 52 weeks of HER2-targeted therapy. Randomisation (ratio 1:1:1) was done centrally with stratification by clinical tumour size, clinical nodal status, hormone-receptor status, and age. The primary endpoint was the pathological complete response in the breast, and analysis was performed on an intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00486668. Findings: Patient accrual started on July 16, 2007, and was completed on June 30, 2011; 529 women were enrolled in the trial. 519 patients had their pathological response determined. Breast pathological complete response was noted in 93 (52·5%, 95% CI 44·9-59·5) of 177 patients in the trastuzumab group, 91 (53·2%, 45·4-60·3) of 171 patients in the lapatinib group (p=0·9852); and 106 (62·0%, 54·3-68·8) of 171 patients in the combination group (p=0·095). The most common grade 3 and 4 toxic effects were neutropenia (29 [16%] patients in the trastuzumab group [grade 4 in five patients (3%), 28 [16%] in the lapatinib group [grade 4 in eight patients (5%)], and 29 [17%] in the combination group [grade 4 in nine patients (5%)]) and grade 3 diarrhoea (four [2%] patients in the trastuzumab group, 35 [20%] in the lapatinib group, and 46 [27%] in the combination group; p<0·0001). Symptomatic congestive heart failure defined as New York Heart Association Class III or IV events occurred in seven (4%) patients in the trastuzumab group, seven (4%) in the lapatinib group, and one (<1%) in the combination group; p=0·185). Interpretation: Substitution of lapatinib for trastuzumab in combination with chemotherapy resulted in similar high percentages of pathological complete response. Combined HER2-targeted therapy produced a numerically but insignificantly higher pathological complete response percentage than single-agent HER2-directed therapy; these findings are consistent with results from other studies. Trials are being undertaken to further assess these findings in the adjuvant setting. Funding: GlaxoSmithKline.

Original languageEnglish (US)
Pages (from-to)1183-1192
Number of pages10
JournalThe Lancet Oncology
Volume14
Issue number12
DOIs
StatePublished - Nov 2013

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Paclitaxel
Doxorubicin
Cyclophosphamide
lapatinib
Breast
Trastuzumab
Therapeutics
Poisons
Random Allocation
Combination Drug Therapy
Neutropenia

ASJC Scopus subject areas

  • Oncology

Cite this

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41) : An open-label, randomised phase 3 trial. / Robidoux, André; Tang, Gong; Rastogi, Priya; Geyer, Charles E.; Azar, Catherine A.; Atkins, James N.; Fehrenbacher, Louis; Bear, Harry D.; Baez-Diaz, Louis; Sarwar, Shakir; Margolese, Richard G.; Farrar, William B.; Brufsky, Adam M.; Shibata, Henry R.; Bandos, Hanna; Paik, Soonmyung; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman.

In: The Lancet Oncology, Vol. 14, No. 12, 11.2013, p. 1183-1192.

Research output: Contribution to journalArticle

Robidoux, A, Tang, G, Rastogi, P, Geyer, CE, Azar, CA, Atkins, JN, Fehrenbacher, L, Bear, HD, Baez-Diaz, L, Sarwar, S, Margolese, RG, Farrar, WB, Brufsky, AM, Shibata, HR, Bandos, H, Paik, S, Costantino, JP, Swain, SM, Mamounas, EP & Wolmark, N 2013, 'Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial', The Lancet Oncology, vol. 14, no. 12, pp. 1183-1192. https://doi.org/10.1016/S1470-2045(13)70411-X
Robidoux, André ; Tang, Gong ; Rastogi, Priya ; Geyer, Charles E. ; Azar, Catherine A. ; Atkins, James N. ; Fehrenbacher, Louis ; Bear, Harry D. ; Baez-Diaz, Louis ; Sarwar, Shakir ; Margolese, Richard G. ; Farrar, William B. ; Brufsky, Adam M. ; Shibata, Henry R. ; Bandos, Hanna ; Paik, Soonmyung ; Costantino, Joseph P. ; Swain, Sandra M. ; Mamounas, Eleftherios P. ; Wolmark, Norman. / Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41) : An open-label, randomised phase 3 trial. In: The Lancet Oncology. 2013 ; Vol. 14, No. 12. pp. 1183-1192.
@article{82d06d0fdbd4451394cd3fabcfe26327,
title = "Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial",
abstract = "Background: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients. Methods: For this open-label, randomised phase 3 trial we recruited women aged 18 years or older with an ECOG performance status of 0 or 1 with operable HER2-positive breast cancer. Each received four cycles of standard doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 intravenously on day 1 every 3 weeks followed by four cycles of weekly paclitaxel (80 mg/m2) intravenously on days 1, 8, and 15, every 4 weeks. Concurrently with weekly paclitaxel, patients received either trastuzumab (4 mg/kg load, then 2 mg/kg intravenously) weekly until surgery, lapatinib (1250 mg orally) daily until surgery, or weekly trastuzumab plus lapatinib (750 mg orally) daily until surgery. After surgery, all patients received trastuzumab to complete 52 weeks of HER2-targeted therapy. Randomisation (ratio 1:1:1) was done centrally with stratification by clinical tumour size, clinical nodal status, hormone-receptor status, and age. The primary endpoint was the pathological complete response in the breast, and analysis was performed on an intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00486668. Findings: Patient accrual started on July 16, 2007, and was completed on June 30, 2011; 529 women were enrolled in the trial. 519 patients had their pathological response determined. Breast pathological complete response was noted in 93 (52·5{\%}, 95{\%} CI 44·9-59·5) of 177 patients in the trastuzumab group, 91 (53·2{\%}, 45·4-60·3) of 171 patients in the lapatinib group (p=0·9852); and 106 (62·0{\%}, 54·3-68·8) of 171 patients in the combination group (p=0·095). The most common grade 3 and 4 toxic effects were neutropenia (29 [16{\%}] patients in the trastuzumab group [grade 4 in five patients (3{\%}), 28 [16{\%}] in the lapatinib group [grade 4 in eight patients (5{\%})], and 29 [17{\%}] in the combination group [grade 4 in nine patients (5{\%})]) and grade 3 diarrhoea (four [2{\%}] patients in the trastuzumab group, 35 [20{\%}] in the lapatinib group, and 46 [27{\%}] in the combination group; p<0·0001). Symptomatic congestive heart failure defined as New York Heart Association Class III or IV events occurred in seven (4{\%}) patients in the trastuzumab group, seven (4{\%}) in the lapatinib group, and one (<1{\%}) in the combination group; p=0·185). Interpretation: Substitution of lapatinib for trastuzumab in combination with chemotherapy resulted in similar high percentages of pathological complete response. Combined HER2-targeted therapy produced a numerically but insignificantly higher pathological complete response percentage than single-agent HER2-directed therapy; these findings are consistent with results from other studies. Trials are being undertaken to further assess these findings in the adjuvant setting. Funding: GlaxoSmithKline.",
author = "Andr{\'e} Robidoux and Gong Tang and Priya Rastogi and Geyer, {Charles E.} and Azar, {Catherine A.} and Atkins, {James N.} and Louis Fehrenbacher and Bear, {Harry D.} and Louis Baez-Diaz and Shakir Sarwar and Margolese, {Richard G.} and Farrar, {William B.} and Brufsky, {Adam M.} and Shibata, {Henry R.} and Hanna Bandos and Soonmyung Paik and Costantino, {Joseph P.} and Swain, {Sandra M.} and Mamounas, {Eleftherios P.} and Norman Wolmark",
year = "2013",
month = "11",
doi = "10.1016/S1470-2045(13)70411-X",
language = "English (US)",
volume = "14",
pages = "1183--1192",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41)

T2 - An open-label, randomised phase 3 trial

AU - Robidoux, André

AU - Tang, Gong

AU - Rastogi, Priya

AU - Geyer, Charles E.

AU - Azar, Catherine A.

AU - Atkins, James N.

AU - Fehrenbacher, Louis

AU - Bear, Harry D.

AU - Baez-Diaz, Louis

AU - Sarwar, Shakir

AU - Margolese, Richard G.

AU - Farrar, William B.

AU - Brufsky, Adam M.

AU - Shibata, Henry R.

AU - Bandos, Hanna

AU - Paik, Soonmyung

AU - Costantino, Joseph P.

AU - Swain, Sandra M.

AU - Mamounas, Eleftherios P.

AU - Wolmark, Norman

PY - 2013/11

Y1 - 2013/11

N2 - Background: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients. Methods: For this open-label, randomised phase 3 trial we recruited women aged 18 years or older with an ECOG performance status of 0 or 1 with operable HER2-positive breast cancer. Each received four cycles of standard doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 intravenously on day 1 every 3 weeks followed by four cycles of weekly paclitaxel (80 mg/m2) intravenously on days 1, 8, and 15, every 4 weeks. Concurrently with weekly paclitaxel, patients received either trastuzumab (4 mg/kg load, then 2 mg/kg intravenously) weekly until surgery, lapatinib (1250 mg orally) daily until surgery, or weekly trastuzumab plus lapatinib (750 mg orally) daily until surgery. After surgery, all patients received trastuzumab to complete 52 weeks of HER2-targeted therapy. Randomisation (ratio 1:1:1) was done centrally with stratification by clinical tumour size, clinical nodal status, hormone-receptor status, and age. The primary endpoint was the pathological complete response in the breast, and analysis was performed on an intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00486668. Findings: Patient accrual started on July 16, 2007, and was completed on June 30, 2011; 529 women were enrolled in the trial. 519 patients had their pathological response determined. Breast pathological complete response was noted in 93 (52·5%, 95% CI 44·9-59·5) of 177 patients in the trastuzumab group, 91 (53·2%, 45·4-60·3) of 171 patients in the lapatinib group (p=0·9852); and 106 (62·0%, 54·3-68·8) of 171 patients in the combination group (p=0·095). The most common grade 3 and 4 toxic effects were neutropenia (29 [16%] patients in the trastuzumab group [grade 4 in five patients (3%), 28 [16%] in the lapatinib group [grade 4 in eight patients (5%)], and 29 [17%] in the combination group [grade 4 in nine patients (5%)]) and grade 3 diarrhoea (four [2%] patients in the trastuzumab group, 35 [20%] in the lapatinib group, and 46 [27%] in the combination group; p<0·0001). Symptomatic congestive heart failure defined as New York Heart Association Class III or IV events occurred in seven (4%) patients in the trastuzumab group, seven (4%) in the lapatinib group, and one (<1%) in the combination group; p=0·185). Interpretation: Substitution of lapatinib for trastuzumab in combination with chemotherapy resulted in similar high percentages of pathological complete response. Combined HER2-targeted therapy produced a numerically but insignificantly higher pathological complete response percentage than single-agent HER2-directed therapy; these findings are consistent with results from other studies. Trials are being undertaken to further assess these findings in the adjuvant setting. Funding: GlaxoSmithKline.

AB - Background: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients. Methods: For this open-label, randomised phase 3 trial we recruited women aged 18 years or older with an ECOG performance status of 0 or 1 with operable HER2-positive breast cancer. Each received four cycles of standard doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 intravenously on day 1 every 3 weeks followed by four cycles of weekly paclitaxel (80 mg/m2) intravenously on days 1, 8, and 15, every 4 weeks. Concurrently with weekly paclitaxel, patients received either trastuzumab (4 mg/kg load, then 2 mg/kg intravenously) weekly until surgery, lapatinib (1250 mg orally) daily until surgery, or weekly trastuzumab plus lapatinib (750 mg orally) daily until surgery. After surgery, all patients received trastuzumab to complete 52 weeks of HER2-targeted therapy. Randomisation (ratio 1:1:1) was done centrally with stratification by clinical tumour size, clinical nodal status, hormone-receptor status, and age. The primary endpoint was the pathological complete response in the breast, and analysis was performed on an intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00486668. Findings: Patient accrual started on July 16, 2007, and was completed on June 30, 2011; 529 women were enrolled in the trial. 519 patients had their pathological response determined. Breast pathological complete response was noted in 93 (52·5%, 95% CI 44·9-59·5) of 177 patients in the trastuzumab group, 91 (53·2%, 45·4-60·3) of 171 patients in the lapatinib group (p=0·9852); and 106 (62·0%, 54·3-68·8) of 171 patients in the combination group (p=0·095). The most common grade 3 and 4 toxic effects were neutropenia (29 [16%] patients in the trastuzumab group [grade 4 in five patients (3%), 28 [16%] in the lapatinib group [grade 4 in eight patients (5%)], and 29 [17%] in the combination group [grade 4 in nine patients (5%)]) and grade 3 diarrhoea (four [2%] patients in the trastuzumab group, 35 [20%] in the lapatinib group, and 46 [27%] in the combination group; p<0·0001). Symptomatic congestive heart failure defined as New York Heart Association Class III or IV events occurred in seven (4%) patients in the trastuzumab group, seven (4%) in the lapatinib group, and one (<1%) in the combination group; p=0·185). Interpretation: Substitution of lapatinib for trastuzumab in combination with chemotherapy resulted in similar high percentages of pathological complete response. Combined HER2-targeted therapy produced a numerically but insignificantly higher pathological complete response percentage than single-agent HER2-directed therapy; these findings are consistent with results from other studies. Trials are being undertaken to further assess these findings in the adjuvant setting. Funding: GlaxoSmithKline.

UR - http://www.scopus.com/inward/record.url?scp=84886721495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886721495&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(13)70411-X

DO - 10.1016/S1470-2045(13)70411-X

M3 - Article

VL - 14

SP - 1183

EP - 1192

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -